4 results
Search Results
2. Response definition criteria for ELISPOT assays revisited.
- Author
-
Moodie, Z., Price, L., Gouttefangeas, C., Mander, A., Janetzki, S., Löwer, M., Welters, M. J. P., Ottensmeier, C., van der Burg, S. H., and Britten, Cedrik M.
- Subjects
- *
T cells , *IMMUNOTHERAPY , *IMMUNE response , *ANTIGENS , *PEPTIDES - Abstract
No consensus has been reached on how to determine if an immune response has been detected based on raw data from an ELISPOT assay. The goal of this paper is to enable investigators to understand and readily implement currently available methods for response determination. We describe empirical and statistical approaches, identifying the strengths and limitations of each approach to allow readers to rationally select and apply a scientifically sound method appropriate to their specific laboratory setting. Five representative approaches were applied to data sets from the CIMT Immunoguiding Program and the response detection and false positive rates were compared. Simulation studies were also performed to compare empirical and statistical approaches. Based on these, we recommend the use of a non-parametric statistical test. Further, we recommend that six medium control wells or four wells each for both medium control and experimental conditions be performed to increase the sensitivity in detecting a response, that replicates with large variation in spot counts be filtered out, and that positive responses arising from experimental spot counts below the estimated limit of detection be interpreted with caution. Moreover, a web-based user interface was developed to allow easy access to the recommended statistical methods. This interface allows the user to upload data from an ELISPOT assay and obtain an output file of the binary responses. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
3. Immune impairment in patients with terminal cancers: influence of cancer treatments and cytomegalovirus infection.
- Author
-
I-Hsuan Chen, Yuen-Liang Lai, Chien-Liang Wu, Yi-Fang Chang, Chen-Chung Chu, I-Fang Tsai, Fang-Ju Sun, and Yen-Ta Lu
- Subjects
- *
IMMUNODEFICIENCY , *CYTOMEGALOVIRUS diseases , *CARCINOGENESIS , *CANCER patients , *T cells , *IMMUNOTHERAPY - Abstract
Although immunodeficiency is usually considered a prerequisite of oncogenesis, a detailed immune profile in cancer has not yet been described. Without such profiling, it is not surprising that there is a vast discrepancy in the responses of cancer patients to immunotherapy. Our results show that the integrity of the immune system deteriorates with cancer progression by displaying a trend toward decreasing levels of functional T cells, including CD4, naïve, and central memory T cells, and an expansion of hyporesponsive populations such as CD28− and CMV-specific T cells. One hundred and one patients constitute the study group for the observational study reported in this paper. Forty-eight patients with newly diagnosed stages III and IV and 53 patients with extensively treated stage IV disease. The costimulatory molecules CD27 and CD28 were downregulated in all patients. Among the proinflammatory cytokines (IL-6, TNF-α, IFN-γ), only IL-6 differed significantly among the groups, increasing as the cancer stage progressed. Plasma IL-7 did not differ among the participants. The relative deficits of naïve T cells in cancer patients may be associated with the downregulation of IL-7Rα expression rather than changes in the circulating levels of IL-7. The downregulation of IL-7Rα expression was shown to be associated with increased levels of intracellular CMV. The present study suggests that the immune impairment in patients with cancer is associated with multiple factors, such as the stage of cancer, consequence of CMV infection and impact of treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
4. Cellular therapy of cancer symposium December 2nd–3rd 2006 Manchester, UK.
- Author
-
Thistlethwaite, Fiona C., Gilham, David E., and Hawkins, Robert E.
- Subjects
- *
CONFERENCES & conventions , *CELLULAR therapy , *IMMUNOTHERAPY , *T cells , *ONCOLOGY conferences - Abstract
Information about several papers discussed at the symposium on cellular therapy of cancer, held in Manchester, England from December 2-3, 2006, is presented. The participants discussed several issues related to gene-modified T cell-based immunotherapies. Those who took part in the discussion included medical experts Balbino Alarcon, Janos Szollosi and Zelig Eshhar.
- Published
- 2007
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.